Henry Schein, Inc. (NASDAQ:HSIC) Shares Sold by Comerica Bank

Comerica Bank decreased its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 6.0% during the 4th quarter, Holdings Channel.com reports. The fund owned 18,954 shares of the company’s stock after selling 1,212 shares during the period. Comerica Bank’s holdings in Henry Schein were worth $1,312,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Schonfeld Strategic Advisors LLC increased its stake in shares of Henry Schein by 357.6% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 24,511 shares of the company’s stock valued at $1,696,000 after purchasing an additional 19,154 shares during the period. AdvisorShares Investments LLC acquired a new stake in shares of Henry Schein in the fourth quarter valued at approximately $6,989,000. Northern Trust Corp increased its stake in shares of Henry Schein by 17.6% in the fourth quarter. Northern Trust Corp now owns 1,376,515 shares of the company’s stock valued at $95,255,000 after purchasing an additional 206,078 shares during the period. Berger Financial Group Inc increased its stake in shares of Henry Schein by 1.6% in the fourth quarter. Berger Financial Group Inc now owns 66,899 shares of the company’s stock valued at $4,629,000 after purchasing an additional 1,031 shares during the period. Finally, Snyder Capital Management L P increased its stake in shares of Henry Schein by 6.2% in the fourth quarter. Snyder Capital Management L P now owns 1,194,802 shares of the company’s stock valued at $82,680,000 after purchasing an additional 69,835 shares during the period. Institutional investors and hedge funds own 96.62% of the company’s stock.

Insider Buying and Selling

In related news, Director Philip A. Laskawy sold 2,604 shares of the firm’s stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total transaction of $184,988.16. Following the completion of the sale, the director now directly owns 24,805 shares in the company, valued at approximately $1,762,147.20. This trade represents a 9.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Bradford C. Connett sold 4,036 shares of the firm’s stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total transaction of $287,161.40. Following the completion of the transaction, the chief executive officer now directly owns 62,688 shares of the company’s stock, valued at $4,460,251.20. This represents a 6.05% decrease in their position. The disclosure for this sale can be found here. 1.08% of the stock is currently owned by insiders.

Henry Schein Trading Down 0.3%

Shares of NASDAQ:HSIC opened at $68.68 on Monday. The stock has a market capitalization of $8.41 billion, a price-to-earnings ratio of 28.26, a PEG ratio of 2.13 and a beta of 0.87. Henry Schein, Inc. has a 1-year low of $60.56 and a 1-year high of $82.49. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. The company has a 50 day moving average price of $67.59 and a 200 day moving average price of $71.46.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Monday, May 5th. The company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.11 by $0.04. The firm had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.24 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The firm’s revenue for the quarter was down .1% compared to the same quarter last year. During the same period last year, the firm posted $1.10 earnings per share. On average, research analysts anticipate that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Jefferies Financial Group raised their price target on shares of Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a research note on Thursday, January 23rd. UBS Group dropped their price target on shares of Henry Schein from $83.00 to $80.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 26th. Barrington Research lowered their price objective on shares of Henry Schein from $90.00 to $86.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 6th. StockNews.com lowered shares of Henry Schein from a “buy” rating to a “hold” rating in a research note on Thursday, April 17th. Finally, Wells Fargo & Company lowered their price objective on shares of Henry Schein from $80.00 to $75.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 6th. Six research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $79.30.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.